(To see other currencies, click on price)
MORE ABOUT THIS BOOK
Main description:
This volume of the Subcellular Biochemistry series is the result of the long-standing research interest of the editor in the molecular mechanism underlying Alzheimer's disease and other amyloid diseases, indicated also by the earlier book in the series (Volume 38), devoted to Alzheimer's disease. The broad coverage within the present amyloidogenesis book represents an attempt to collate current knowledge relating to the proteins and peptides involved in most of the known amyloid diseases, together with some amyloid/fibril-forming proteins and peptides that are not involved in diseases. Thus, the range of topics included is comprehensive and furthermore it was thought appropriate to include both basic science and clinical presentation of the subjects under discussion.
Contents:
I. Introduction
1. Introduction and Technical Survey; J. Robin Harris and Nathaniel G. Milton
II. Basic Science
2. Fibril Formation by Short Synthetic Peptides; Andrew Smith
3. In vitro Oligomerization and Fibrillogenesis of Amyloid-beta Peptides; Nuria Benseny-Cases, Oksana Klementieva and Josep Cladera
4. Tau Fibrillogenesis; Nitin Chaudhary and Ramakrishnan Nagaraj
5. Prion protein Aggregation and Fibrillogenesis In vitro; Jan Stoehr
6. -Synuclein Aggregation and Modulating Factors; Katerina E. Paleologou and Omar M. A. El-Agnaf
7. Pathological Self-aggregation of 2-microglobulin: A Challenge for Protein Biophysics; Gennaro Esposito, Alessandra Corazza, and Vittorio Bellotti
8. Islet amyloid polypeptide - Aggregation and fibrillogenesis in vitro and its Inhibition; Janine Seeliger and Roland Winter
9. Mechanisms of Transthyretin Aggregation and Toxicity; Robert J. Gasperini, David W. Klaver, Xu Hou, Marie-Isabel Aguilar and David H. Small
10. Fibrillogenesis of Huntingtin and Other Glutamine Containing Proteins; Yuri L. Lyubchenko, Alexey V. Krasnoslobodtsev and Sorin Luca
11. Aggregation and Fibrillogenesis of Proteins not Associated with Disease - A few Case Studies; Moritz Lasse, Juliet A. Gerrard and F. Grant Pearce
12. Experimental Inhibition of Peptide Fibrillogenesis by Synthetic Peptides, Carbohydrates and Drugs; Alagiri Srinivasan
13. Experimental inhibition of fibrillogenesis and neurotoxicity by amyloid-beta (A ) and other disease-related peptides/proteins by plant extracts and herbal compounds; Suresh Kumar, Edward Okello and J. Robin Harris
III. Clinical Science: The Cerebral and Systemic Amyloid Diseases
Pathogenesis and therapeutic consideration of the major disorders
14. Alzheimer's Disease; Vanessa J. De-Paula, Marcia Radanovic, Breno S. Diniz, Orestes V. Forlenza
15. Modeling the Polyglutamine Aggregation Pathway in Huntington's Disease: from Basic Studies to Clinical Applications;
Keizo Sugaya
16. Parkinson's Disease; Timothy R. Mhyre, James T. Boyd, Robert W. Hamill, and Kathleen Maguire-Zeiss
17. Human Prion Diseases: From Kuru to Variant Creutzfeldt-Jakob Diseasae; Beata Sikorska and Pawel P. Liberski
18. Animal Prion Diseases; Otto Windl and Mike Dawson
19. 2-microglobulin Amyloidosis; Dorthe B. Corlin and Niels H.H. Heegaard
20. Systemic AA Amyloidosis; Jennifer H Pinney and Helen J Lachmann
21. Familial Amyloidotic Polyneuropathy and Transthyretin; Takamura Nagasaka 22. The Challenge of Systemic Immunoglobulin Light-chain Amyloidosis (AL); Giovanni Palladini and Raymond L Comenzo
PRODUCT DETAILS
Publisher: Springer
Publication date: December, 2012
Pages: 490
Weight: 1226g
Availability: Available
Subcategories: General Issues, General Practice
Publisher recommends
From the same series
